X-Gen Pharmaceu Patent-Cliff Exposure & CMS Drug Spending Portfolio

X-Gen Pharmaceu (US): 4 reconciled FDA prescription therapies, $3.2M 2024 CMS Part D & Medicaid spend, and $239 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$3.2M
2024 Medicare Part D Spend$2.2M
2024 Medicaid Spend$1.0M
California HCAI SB 17 FilingsSpecialty launch notice ($239 intro WAC)